Semaglutide Cuts Cardiovascular Events in Obesity Without Diabetes

SELECT establishes that semaglutide 2.4 mg reduces major adverse cardiovascular events in nondiabetic patients with established cardiovascular disease and overweight or obesity, extending the drug's cardioprotective indication beyond glycemic management.

semaglutideGLP-1 receptor agonistobesityoverweightcardiovascular diseaseMACEsecondary preventionrandomized controlled trialSELECTWegovy Endocrinology / Obesity

Background Information

Semaglutide cuts heart risks in obesity without diabetes.

Semaglutide might offer cardiovascular protection for patients with obesity who do not have diabetes, addressing a critical need in this population. Semaglutide reduced the risk of cardiovascular events from 8.0% to 6.5% compared to placebo (hazard ratio, 0.80; 95% CI, 0.72 to 0.90; P<0.001). The study suggests semaglutide could be used beyond diabetes treatment for cardiovascular risk reduction in obese patients without diabetes, although the adverse event rate needs consideration. Semaglutide significantly reduces cardiovascular events in obese patients without diabetes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH, SELECT Trial Investigators

Citation: Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →